Product Description
Lusutrombopag is used to treat thrombocytopenia (low platelets in the blood) in adults with chronic liver disease who are scheduled to have a medical or dental procedure. It works by stimulating the bone marrow to produce more platelets. (Sourced from: https://www.mayoclinic.org/drugs-supplements/lusutrombopag-oral-route/description/drg-20443925)
Mechanisms of Action: TPO Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovakia | Spain | Sweden | United Kingdom | United States
Approved Indications: Thrombocytopenia
Known Adverse Events: Headache
Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Anemia, Aplastic
Phase 3: Thrombocytopenia
Phase 2: Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024KY402 | P2 |
Recruiting |
Thrombocytopenia |
2025-11-30 |
|
| LNA-2024 | P4 |
Not yet recruiting |
Anemia, Aplastic |
2025-06-01 |
|
| ChiCTR2400084012 | N/A |
Not yet recruiting |
Anemia, Aplastic |
2025-04-30 |
|
| A pilot study to evaluate the efficacy and safety of lusutrombopag in ITP patients | N/A |
Not yet recruiting |
Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia |
2024-11-30 |